Three Protocols Designed to Individualize and Maximize Anti-Cancer Drug Therapy


The role that attaining maximum drug dosage intensity plays in many anti-cancer protocols is a major one, particularly in those protocols that attempt to totally eradicate the neoplasm. A classic approach to facilitate this process utilizes stem cell transplants as well as the use of hematopoetic growth factors. However, problems arise with both allogenic and autologous transplants as well as from the significant variability in drug tolerance between individual patients. With average fixed dose protocols, these problems substantially limit the ability to optimize drug dosage. We attempted to circumvent this difficulty by using low dose continuous infusional therapy of variable duration depending upon the patient’s response, together with simultaneous hematopoietic growth factor support. This paper presents our results with three drugs, doxorubicin, ifosphamide, and vinorelbine. With these protocols, we were able to individualize and optimize the amount of drug delivered to each patient, as well as to substantially increase the drug dosage intensity of each of these agents.

Share and Cite:

Weiss, A. and Stoloff, I. (2015) Three Protocols Designed to Individualize and Maximize Anti-Cancer Drug Therapy. Journal of Cancer Therapy, 6, 1103-1113. doi: 10.4236/jct.2015.612120.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Toffoli, G., Giodini, L., Buonadonna, A., Berretta, M., De Paoli, A., Scalone, S., Miolo, G., Mini, E., Nobili, S., Lonardi, S., Pella, N., Lo Re, G., Montico, M., Roncato, R., Dreussi, E., Gagno, S. and Cecchin, E. (2015) Clinical Validity of a DPYD-Based Pharmacogenetic Test to Predict Severe Toxicity to Fluoropyrimidines. International Journal of Cancer, 137, 2971-2980.
[2] Nakamura, M., Yamada, Y., Muro, K., Takahashi, K., Baba, H., Sasaki, Y., Komatsu, Y., Satoh, T., Mishima, H., Watanabe, M., Sakata, Y., Morita, S., Shimada, Y. and Sugihara, K. (2015) The SOFT Trial: A Phase III Study of the Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidine S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer. Future Oncology, 11, 1471-1478.
[3] Yee, S.W., Gong, L., Badagnani, I., Giacomini, K.M., Klein, T.E. and Altman, R.B. (2010) SLC19A1 Pharmacogenomics Summary. Pharmacogenetics and Genomics, 20, 708-715.
[4] Siegel, D., Chao Y. and Ross, D. (2012) NAD(P)H:Quinone Oxidoreductase 1 (NQO1) in the Sensitivity and Resistance to Antitumor Quinones. Biochemical Pharmacology, 83, 1033-1040.
[5] Gibson, L.F., Fortney, J., Magro, G., Ericson, S.G., Lynch, J.P. and Landreth, K.S. (1999) Regulation of BAX and BCL-2 EXPRESsion in Breast Cancer Cells by Chemotherapy. Breast Cancer Research and Treatment, 55, 107-117.
[6] Geng, X., Xie, L. and Xing, H. (2015) PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells in Vitro and in Vivo. Technology in Cancer Research & Treatment, pii: 1533034615597366.
[7] Arques, O., Chicote, I., Puig, I., Tenbaum, S.P., Argiles, G., Dienstmann, R., Fernandez, N., Caratu, G., Matito, J., Silberschmidt, D., Rodon, J., Landolfi, S., Prat, A., Espin, E., Charco, R., Nuciforo, P., Vivancos, A., Shao, W., Tabernero, J. and Palmer, H.G. (2015) Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research, in Press.
[8] Hofman, J., Skarka, A., Havrankova, J. and Wsol, V. (2015) Pharmacokinetic Interactions of Breast Cancer Chemotherapeutics with Human Doxorubicin Reductases. Biochemical Pharmacology, 96, 168-178.
[9] Voller, S., Boos, J., Krischke, M., Würthwein, G., Kontny, N.E., Boddy, A.V. and Hempel, G. (2015) Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clinical Pharmacokinetics, 54, 1139-1149.
[10] Datta, A., Bhasin, N., Kim, H., Ranjan, M., Rider, B., Abd Elmageed, Z.Y., Mondal, D., Agrawal, K.C. and Abdel-Mageed, A.B. (2015) Selective Targeting of FAK-Pyk2 axis by Alpha-Naphthoflavone Abrogates Doxorubicin Resistance in Breast Cancer Cells. Cancer Letters, 362, 25-35.
[11] DeVita, V., Lawrence, T. and Rosenberg, S. (2014) Devita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th Edition, Wolters Kluwer, Philadelphia.
[12] Sweetenham, J.W. (1995) The Importance of Dose and Schedule in Cancer Chemotherapy: Haematological Cancer. Anticancer Drugs, 6, 7-15.
[13] Lin, K.Y., Ye, H., Han, B.W., Wang, W.T., Wei, P.P., He, B., Li, X.J. and Chen, Y.Q. (2015) Genome-Wide Screen Identified Let-7c/miR-99a/miR-125b Regulating Tumor Progression and Stem-Like Properties in Cholangiocarcinoma. Oncogene, Published Online.
[14] Prindull, G. (2015) Potential Gene Interactions in the Cell Cycles of Gametes, Zygotes, Embryonic Stem Cells and the Development of Cancer. Frontiers in Oncology, 5, 200.
[15] Franqui-Machin, R., Wendlandt, E.B., Janz, S., Zhan, F. and Tricot, G. (2015) Cancer Stem Cells Are the Cause of Drug Resistance in Multiple Myeloma: Fact or Fiction? Oncotarget, Published Online.
[16] Patel, S.R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M.A., Hays, C. and Benjamin, R.S. (1997) High-Dose Ifosfamide in Bone and Soft Tissue Sarcomas: Results of Phase II and Pilot Studies—Dose-Response and Schedule Dependence. Journal of Clinical Oncology, 15, 2378-2384.
[17] Magnan, H., Goodbody, C.M., Riedel, E., Pratilas, C.A., Wexler, L.H. and Chou, A.J. (2015) Ifosfamide Dose-Intensification for Patients with Metastatic Ewing sarcoma. Pediatric Blood & Cancer, 62, 594-597.
[18] Honkoop, A.H., van der Wall, E., Feller, N., Schuurhuis, G.J., van der Vijgh, W.J., Boven, E., van Groeningen, C.J., Giaccone, G., Hoekman, K., Vermorken, J.B., Wagstaff, J. and Pinedo, H.M. (1997) Multiple Cycles of High-Dose Doxorubicin and Cyclophosphamide with G-CSF Mobilized Peripheral Blood Progenitor Cell Support in Patients with Metastatic Breast Cancer. Annals of Oncology, 8, 957-962.
[19] Liu, L., Qu, Q., Jiao, W., Zhang, Y., Li, X., Ding, C. and Wu, D. (2015) Increasing Aclarubicin Dose in Low-Dose Cytarabine and Aclarubicin in Combination with Granulocyte Colony-Stimulating Factor (CAG Regimen) Is Efficacious as Salvage Chemotherapy for Relapsed/Refractory Mixed-Phenotype Acute Leukemia. Leukemia Research, 39, 805-811.
[20] Untch, M., Fasching, P.A., Konecny, G.E., et al. (2011) PREPARE Trial: A Randomized Phase III Trial Comparing Preoperative, Dose-Dense, Dose-Intensified Chemotherapy with Epirubicin, Paclitaxel and CMF versus a Standard-Dosed Epirubicin/Cyclophosphamide Followed by Paclitaxel ± Darbepoetin Alfa in Primary Breast Cancer—Results at the Time of Surgery. Annals of Oncology, 22, 1988-1989.
[21] Oberlin, O., Rey, A., Sanchez de Toledo, J., Martelli, H., Jenney, M.E., Scopinaro, M., Bergeron, C., Merks, J.H., Bouvet, N., Ellershaw, C., Kelsey, A., Spooner, D. and Stevens, M.C. (2012) Randomized Comparison of Intensified Six-Drug versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results from the International Society of Pediatric Oncology MMT95 Study. Journal of Clinical Oncology, 30, 2457-2465.
[22] Kim, D.S., Kang, K.W., Lee, S.R., Park, Y., Sung, H.J., Kim, S.J., Choi, C.W. and Kim, B.S. (2015) Comparison of Consolidation Strategies in Acute Myeloid Leukemia: High-Dose Cytarabine Alone versus Intermediate-Dose Cytarabine Combined with Anthracyclines. Annals of Hematology, 94, 1485-1492.
[23] Caroli-Bosc, F.X., Van Laethem, J.L., Michel, P., Gay, F., Hendlisz, A., Forget, F. and Bleiberg, H. (2001) A Weekly 24-h Infusion of High-Dose 5-Fluorouracil (5-FU)+Leucovorin and Bi-Weekly Cisplatin (CDDP) Was Active and Well Tolerated in Patients with Non-Colon Digestive Carcinomas. European Journal of Cancer, 37, 1828-1832.
[24] Ramsingh, G., Westervelt, P., McBride, A., et al. Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML. Leukemia & Lymphoma, 36, 589-593.
[25] Dartigeas, C., Van Den Neste, E., Berthou, C., Maisonneuve, H., Leprêtre, S., Dilhuydy, M.S., Béné, M.C., Nguyen-Khac, F., Letestu, R., Cymbalista, F., De Guibert, S., Aurran, T., Laribi, K., Vilque, J.P., Tournilhac, O., Delmer, A., Feugier, P., Cazin, B., Michallet, A.S., Lévy, V., Troussard, X., Delepine, R., Tavernier, E., Colombat, P. and Leblond, V. (2015) Evaluating Abbreviated Induction with Fludarabine, Cyclophosphamide, and Dose-Dense Rituximab in Elderly Patients with Chronic Lymphocytic Leukemia. Leukemia & Lymphoma, 1-19.
[26] Hofmann, M.A., Gabriel, V., Milling, A., Kiecker, F., Sterry, W. and Trefzer, U. (2007) High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma. Chemotherapy, 53, 422-428.
[27] Ostrow, S., Egorin, M., Aisner, J., Bachur, N. and Wiernik, P.H. (1980) High-Dose Cis-Diamminedichloro-Platinum Therapy in Patients with Advanced Breast Cancer: Pharmacokinetics, Toxicity, and Therapeutic Efficacy. Cancer Clinical Trials, 3, 23-27.
[28] Hastings, C., Gaynon, P.S., Nachman, J.B., Sather, H.N., Lu, X., Devidas, M. and Seibel, N.L. Increased Post-Induction Intensification Improves Outcome in Children and Adolescents with a Markedly Elevated White Blood Cell Count (≥200 × 10(9) /l) with T Cell Acute Lymphoblastic Leukaemia but Not B Cell Disease. A Report from the Children’s Oncology Group.
[29] Mulherin, B.P., Brames, M.J. and Einhorn, L.H. (2015) Long-Term Survival with Paclitaxel and Gemcitabine for Germ Cell Tumors after Progression Following High-Dose Chemotherapy with Tandem Transplant. American Journal of Clinical Oncology, 38, 373-6SA.
[30] Beausoleil, M., Ernst, D.S., Stitt, L. and Winquist, E. (2012) Consolidative High-Dose Chemotherapy after Conventional-Dose Chemotherapy as First Salvage Treatment for Male Patients with Metastatic Germ Cell Tumours. Canadian Urological Association Journal, 6, 111-114.
[31] Suleiman, Y., Siddiqui, B.K., Brames, M.J., et al. (2013) Salvage Therapy with High-Dose Chemotherapy and Peripheral Blood Stem Cell Transplant in Patients with Primary Mediastinal Nonseminomatous Germ Cell Tumors. Biology of Blood and Marrow Transplantation, 19, 161-163.
[32] Henderson, I.C., Hayes, D.F. and Gelman, R. (1988) Dose-Response in the Treatment of Breast Cancer: A Critical Review. Journal of Clinical Oncology, 6, 1501-1515.
[33] Hortobagyi, G.N. (1999) High-Dose Chemotherapy for Primary Breast Cancer: Facts versus Anecdotes. Journal of Clinical Oncology, 17, 25-29.
[34] Lalle, M., De Rosa, L., Perillo, A., Scambia, G., D’Aprile, M. and Antimi, M. (2004) High-Dose Chemotherapy for Metastatic Breast Cancer. Clinical Therapeutics, 155, 305.
[35] Tjan-Heijnen, V.C., Postmus, P.E. and Wagener, D.J. (1997) Dose Intensification of Chemotherapy and the Role of Granulocyte Colony Stimulating Factor and Granulocyte Macrophage Colony Stimulating Factor in Small Cell Lung Cancer. Anticancer Drugs, 8, 549-564.
[36] Liu, D., Zheng, X., Chen, J., Liu, G., Xu, Y., Shen, Y., Xie, L., Zhao, W., Jiang, G. and Fan, M. (2015) Induction Chemotherapy with Cetuximab, Vinorelbine-Cisplatin Followed by Thoracic Radiotherapy and Concurrent Cetuximab, Vinorelbine-Cisplatin in Patients with Unresectable Stage III Non-Small Cell Lung Cancer. Lung Cancer, 89, 249-254.
[37] Meropol, N.J., Miller, L.L., Korn, E.L., Braitman, L.E., MacDermott, M.L. and Schuchter, L.M. (1992) Severe Myelosuppression Resulting from Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy. Journal of the National Cancer Institute, 84, 1201-1203.
[38] Rowinsky, E., Sartorius, S. and Grochow, L. (1992) Phase I and Pharmacologic Study of Topotecan, an Inhibitor of Topoisomerase I, with Granulocyte Colony-Stimulating Factor (G-CSF): Toxicologic Differences between Concurrent and Post-Treatment G-CSF Administration. Proc Asco, 11, 284.
[39] Rowinsky, E.K., Grochow, L.B. and Sartorius, S.E. (1996) Phase I and Pharmacologic Study of High Doses of the Topoisomerase I Inhibitor Topotecan with Granulocyte Colony-Stimulating Factor in Patients with Solid Tumors. Journal of Clinical Oncology, 14, 1224-1235.
[40] Weiss, A.J. and Lackman, R.D. (1994) Dose Intensification by the Simultaneous Use of rh-G-CSF and Anti-Cancer Chemotherapy. International Journal of Oncology, 6, 329-332.
[41] Weiss, A.J. and Lackman, R.D. (2002) A Comparison of Human G-Csf and Human Gm-Csf Given Concurrently with Anti-Cancer Chemotherapy. Oncology Reports, 9, 945-950.
[42] Lokich, J.J. (2006) Same Day Pegfilgrastim and CHOP Chemotherapy for Non-Hodgkin Lymphoma. American Journal of Clinical Oncology, 29, 361-363.
[43] Lokich, J. (1999) Single-Dose Granulocyte Colony-Stimulating Factor Concomitant with Multifractionated Dose Chemotherapy: A Strategy for Maintaining Dose Intensity. Cancer Investigation, 17, 547-550.
[44] Weiss, A.J., Stoloff, I.L., Simoes, A.C. and Lackman, R.D. (2014) The Relation between the Initial Type of Schedule Used to Administer Doxorubicin and Long-Term Doxorubicin Cardiotoxicity. Journal of Cancer Therapy, 5, 1145-1152.
[45] Weiss, A.J., Sabol, J. and Lackman, R.D. (1999) Concurrent Administration of Vinorelbine with Recombinant Human Granulocyte Colony-Stimulating Factor: An Effective Method of Increasing Dose Intensity. American Journal of Clinical Oncology, 22, 38-41.
[46] Smith, T.J., Bohlke, K., Lyman, G.H., et al. (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, Published Online.
[47] Bunn Jr., P.A., Crowley, J., Kelly, K., Hazuka, M.B., Beasley, K., Upchurch, C., Livingston, R., Weiss, G.R., Hicks, W.J. and Gandara, D.R. (1995) Chemoradiotherapy with or without Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Limited-Stage Small-Cell Lung Cancer: A Prospective Phase III Randomized Study of the Southwest Oncology Group. Journal of Clinical Oncology, 13, 1632-1641. Erratum in: Journal of Clinical Oncology, 13, 286.
[48] Lipson, E.J., Sharfman, W.H., Chen, S., McMiller, T.L., Pritchard, T.S., Salas, J.T., Sartorius-Mergenthaler, S., Freed, I., Ravi, S., Wang, H., Luber, B., Sproul, J.D., Taube, J.M., Pardoll, D.M. and Topalian, S.L. (2015) Safety and Immunologic Correlates of Melanoma GVAX, a GM-CSF Secreting Allogeneic Melanoma Cell Vaccine Administered in the Adjuvant Setting. Journal of Translational Medicine, 13, 214.
[49] Edmonson, H.J., Long, J.H. and Kvols, K.L. (1997) Can Molgramostim Enhance the Antitumor Effects of Cytotoxic Drugs in Patients with Advanced Sarcomas? Annals of Oncology, 8, 637-641.
[50] Huang, C.C., Kuo, K.K., Cheng, T.C., Chuang, C.H., Kao, C.H., Hsieh, Y.C., Cheng, K.H., Wang, J.Y., Cheng, C.M., Chen, C.S. and Cheng, T.L. (2015) Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. PLoS ONE, 10, e0133470.
[51] van Broekhoven, C.L., Parish, C.R., Demangel, C., Britton, W.J. and Altin, J.G. (2004) Targeting Dendritic Cells with Antigen-Containing Liposomes: A Highly Effective Procedure for Induction of Antitumor Immunity and for Tumor Immunotherapy. Cancer Research, 64, 4357-4365.
[52] Gupta, S., Termini, J.M., Rivas, Y., Otero, M., Raffa, F.N., Bhat, V., Farooq, A. and Stone, G.W. (2015) A Multi-Trimeric Fusion of CD40L and gp100 Tumor Antigen Activates Dendritic Cells and Enhances Survival in a B16-F10 Melanoma DNA Vaccine Model. Vaccine, in Press.
[53] Li, H., Wang, C., Yu, J., Cao, S., Wei, F., Zhang, W., Han, Y. and Ren, X.B. (2009) Dendritic Cell-Activated Cytokine-Induced Killer Cells Enhance the Anti-Tumor Effect of Chemotherapy on Non-Small Cell Lung Cancer in Patients after Surgery. Cytotherapy, 11, 1076-1083.
[54] Arndt, C.A., Koshkina, N.V., Inwards, C.Y., Hawkins, D.S., Krailo, M.D., Villaluna, D., Anderson, P.M., Goorin, A.M., Blakely, M.L., Bernstein, M., Bell, S.A., Ray, K., Grendahl, D.C., Marina, N. and Kleinerman, E.S. (2010) Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report from the Children’s Oncology Group. Clinical Cancer Research, 16, 4024-4030.
[55] Palombi, M., Niscola, P., Tendas, A., Trawinska, M.M., Scaramucci, L., Giovannini, M., Fratoni, S., Perrotti, A. and de Fabritiis, P. (2013) Simultaneous Occurrence of Large B-Cell Non-Hodgkin Lymphoma and Acute Myeloid Leukaemia in an Elderly Patient: Complete Remissions of Both Diseases by Rituximab-Bendamustine Regimen Combined to Hypomethylating Therapy. Journal of Chemotherapy, 25, 247-249.
[56] Cantarow, A. and Zagerman, A.J. (1964) Fluorouracil Inhibition of Teserone-Stimulated Growth of Seminal Vesicles. Proceedings of the Society for Experimental Biology and Medicine, 115, 1052-1054.
[57] Paschkis, K.E., Bartuska, D., Zagerman, J., Goddard, J.W. and Cantarow, A. (1959) Effect of 5-Fluorouracil on Noncancerous Tissue Growth. Cancer Research, 19, 1196-1203.
[58] Zagerman, J. and Cantarow, A. (1962) 5-Fluorouracil Inhibition of Testosterone-Stimulated Growth of Seminal Vesicles. Cancer Chemotherapy Reports, 22, 37-38.
[59] ISMP Canada (2007) Fluorouracil Incident Root Cause Analysis. April 30, 2007 (Formatted for Posting on the Alberta Cancer Board Website on May 23, 2007). ISMP Canada. Fluorouracil Incident RCA: Follow-Up. ISMP Canada Safety Bulletin, 7, 1-4.
[60] Biffi, R., de Braud, F., Orsi, F., Pozzi, S., Mauri, S., Goldhirsch, A., Nolè, F. and Andreoni, B. (1998) Totally Implantable Central Venous Access Ports for Long-Term Chemotherapy. A Prospective Study Analyzing Complications and Costs of 333 Devices with a Minimum Follow-Up of 180 Days. Annals of Oncology, 9, 767-773.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.